Agnes Fogo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11458159/publications.pdf

Version: 2024-02-01

68 papers	8,904 citations	66343 42 h-index	102487 66 g-index
68 all docs	68 docs citations	68 times ranked	5197 citing authors

#	Article	IF	Citations
1	The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney International, 2009, 76, 534-545.	5.2	1,028
2	The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney International, 2009, 76, 546-556.	5.2	892
3	Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature, 1995, 377, 748-750.	27.8	821
4	Oxford Classification of IgA nephropathy 2016: anÂupdate from the IgA Nephropathy Classification Working Group. Kidney International, 2017, 91, 1014-1021.	5.2	748
5	Bone morphogenetic protein 4 regulates the budding site and elongation of the mouse ureter. Journal of Clinical Investigation, 2000, 105, 863-873.	8.2	370
6	Role of the Angiotensin Type 2 Receptor Gene in Congenital Anomalies of the Kidney and Urinary Tract, CAKUT, of Mice and Men. Molecular Cell, 1999, 3, 1-10.	9.7	357
7	Glomerular hemodynamic changes vs. hypertrophy in experimental glomerular sclerosis. Kidney International, 1989, 35, 654-660.	5.2	328
8	Glomerular hypertrophy in minimal change disease predicts subsequent progression to focal glomerular sclerosis. Kidney International, 1990, 38, 115-123.	5.2	247
9	Morphologic and Clinical Features of Fibrillary Glomerulonephritis Versus Immunotactoid Glomerulopathy. American Journal of Kidney Diseases, 1993, 22, 367-377.	1.9	225
10	Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans: A report from the African American Study of Kidney Disease (AASK) Trial. Kidney International, 1997, 51, 244-252.	5.2	216
11	Effects of antihypertensive drugs on glomerular morphology. Kidney International, 1989, 36, 626-635.	5.2	213
12	Bradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition. Kidney International, 1993, 44, 545-550.	5.2	186
13	Modulation of plasminogen activator inhibitor-1 in vivo : A new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition. Kidney International, 1997, 51, 164-172.	5.2	180
14	Angiotensin converting enzyme gene polymorphism: Potential silencer motif and impact on progression in IgA nephropathy. Kidney International, 1996, 49, 571-577.	5.2	171
15	Accelerated fibrosis and collagen deposition develop in the renal interstitium of angiotensin type 2 receptor null mutant mice during ureteral obstruction Rapid Communication. Kidney International, 1998, 53, 937-944.	5.2	160
16	Endothelin receptor antagonism is protective in in vivo acute cyclosporine toxicity. Kidney International, 1992, 42, 770-774.	5.2	159
17	Blood pressure-independent effect of angiotensin inhibition on vascular lesions of chronic renal failure. Kidney International, 1992, 42, 46-55.	5.2	154
18	Developmental expression of renal angiotensin II receptor genes in the mouse. Kidney International, 1995, 47, 140-147.	5.2	147

#	Article	IF	Citations
19	Cause of variable therapeutic efficiency of angiotensin converting enzyme inhibitor on glomerular lesions. Kidney International, 1991, 40, 195-202.	5.2	141
20	A Multicenter Application and Evaluation of the Oxford Classification of IgA Nephropathy in Adult Chinese Patients. American Journal of Kidney Diseases, 2012, 60, 812-820.	1.9	135
21	Evidence that bone morphogenetic protein 4 has multiple biological functions during kidney and urinary tract development. Kidney International, 2003, 63, 835-844.	5.2	109
22	Focal segmental glomerulosclerosis. Pediatric Nephrology, 1996, 10, 374-391.	1.7	101
23	Glucocorticoid activates glomerular antioxidant enzymes and protects glomeruli from oxidant injuries. Kidney International, 1991, 40, 291-301.	5.2	100
24	Expression of decorin, biglycan, and collagen type I in human renal fibrosing disease. Kidney International, 2000, 57, 487-498.	5.2	96
25	Serial micropuncture analysis of single nephron function in subtotal renal ablation. Kidney International, 1988, 33, 855-867.	5.2	95
26	Importance of angiogenic action of angiotensin II in the glomerular growth of maturing kidneys. Kidney International, 1990, 38, 1068-1074.	5.2	95
27	Angiotensin converting enzyme inhibitor modulates glomerular function and structure by distinct mechanisms. Kidney International, 1994, 45, 537-543.	5.2	93
28	COMBINED ANTAGONISM OF ENDOTHELIN A/B RECEPTORS LINKS ENDOTHELIN TO VASOCONSTRICTION WHEREAS ANGIOTENSIN II EFFECTS FIBROSIS. Transplantation, 1995, 60, 89-95.	1.0	91
29	Evidence for a Pathogenic Linkage Between Glomerular Hypertrophy and Sclerosis. American Journal of Kidney Diseases, 1991, 17, 666-669.	1.9	84
30	Intrarenal localization of angiotensin II type 1 receptor mRNA in the rat. Kidney International, 1993, 43, 1229-1235.	5.2	74
31	Angiotensinogen gene null-mutant mice lack homeostatic regulation of glomerular filtration and tubular reabsorption. Kidney International, 1998, 53, 617-625.	5.2	74
32	Communication between myocytes and fibroblasts in cardiac remodeling in angiotensin chimeric mice. Journal of Clinical Investigation, 1999, 103, 1451-1458.	8.2	70
33	CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease. American Journal of Kidney Diseases, 2019, 73, 218-229.	1.9	68
34	Macrophage Cyclooxygenase-2 Protects Against Development of Diabetic Nephropathy. Diabetes, 2017, 66, 494-504.	0.6	66
35	The renal lesions that develop in neonatal mice during angiotensin inhibition mimic obstructive nephropathy. Kidney International, 1999, 55, 1683-1695.	5.2	62
36	Evidence from the Oxford Classification cohort supports the clinical value of subclassification ofÂfocal segmental glomerulosclerosis in IgAÂnephropathy. Kidney International, 2017, 91, 235-243.	5.2	62

#	Article	IF	Citations
37	Hypohalous Acids Contribute to Renal Extracellular Matrix Damage in Experimental Diabetes. Diabetes, 2015, 64, 2242-2253.	0.6	54
38	Novel parietal epithelial cell subpopulations contribute to focal segmental glomerulosclerosis and glomerular tip lesions. Kidney International, 2019, 96, 80-93.	5.2	50
39	Is focal segmental glomerulosclerosis really focal? Distribution of lesions in adults and children. Kidney International, 1995, 47, 1690-1696.	5.2	49
40	Angiotensin-converting enzyme 2 amplification limitedÂto the circulation does not protect miceÂfromÂdevelopment of diabetic nephropathy. Kidney International, 2017, 91, 1336-1346.	5.2	49
41	Effect of heparin on the glomerular structure and function of remnant nephrons. Kidney International, 1988, 34, 638-644.	5.2	46
42	Internephron heterogeneity of growth factors and sclerosisâ€"Modulation of platelet-derived growth factor by angiotensin II. Kidney International, 1995, 47, 131-139.	5.2	46
43	Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis: Findings From the CureGN Study. Kidney International Reports, 2018, 3, 1373-1384.	0.8	39
44	Health-related quality of life in glomerular disease. Kidney International, 2019, 95, 1209-1224.	5.2	38
45	SEVERE ENDOTHELIAL INJURY IN A RENAL TRANSPLANT PATIENT RECEIVING CYCLOSPORINE. Transplantation, 1990, 49, 1190-1191.	1.0	36
46	Effects of Prolonged Growth Hormone Administration in Rats with Chronic Renal Insufficiency. Pediatric Research, 1992, 31, 406-410.	2.3	36
47	Potent antihypertrophic effect of the bradykinin B2 receptor system on the renal vasculature. Kidney International, 1999, 56, 509-516.	5.2	31
48	Mechanism of the Unique Susceptibility of Deep Cortical Glomeruli of Maturing Kidneys to Severe Focal Glomerular Sclerosis. Pediatric Research, 1990, 28, 270-276.	2.3	28
49	Strategic locus for the activation of the superoxide dismutase gene in the nephron. Kidney International, 1995, 47, 536-546.	5.2	26
50	The Effect of Selective Growth Hormone Defect in the Progression of Glomerulosclerosis. American Journal of Kidney Diseases, 1994, 23, 302-312.	1.9	24
51	An adolescent with relapsing nephrotic syndrome: Minimal-change disease versus focal-segmental glomerulosclerosis versus C1q nephropathy. American Journal of Kidney Diseases, 1997, 29, 966-970.	1.9	20
52	A novel in vivo mechanism for angiotensin type 1 receptor regulation. Kidney International, 1997, 52, 345-355.	5.2	18
53	Longitudinal Changes in Health-Related Quality of Life in Primary Glomerular Disease: Results From the CureGN Study. Kidney International Reports, 2020, 5, 1679-1689.	0.8	17
54	RENAL ANGIOTENSIN CONVERTING ENZYME PROMOTES RENAL DAMAGE DURING URETERAL OBSTRUCTION. Journal of Urology, 1998, 160, 1070-1074.	0.4	15

#	Article	IF	Citations
55	Novel pathologic scoring tools predict end-stage kidney disease in light chain (AL) amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 205-211.	3.0	14
56	The Molecular Basis of Increased Glomerulosclerosis after Blockade of the Renin Angiotensin System in Growth Hormone Transgenic Mice. Molecular Medicine, 1994, 1, 104-115.	4.4	10
57	Lipopolysaccharide Pretreatment Prevents Medullary Vascular Congestion following Renal Ischemia by Limiting Early Reperfusion of the Medullary Circulation. Journal of the American Society of Nephrology: JASN, 2022, 33, 769-785.	6.1	10
58	Endothelin: potential role in development and disease. Pediatric Nephrology, 1993, 7, 876-880.	1.7	7
59	RENAL ANGIOTENSIN CONVERTING ENZYME PROMOTES RENAL DAMAGE DURING URETERAL OBSTRUCTION. Journal of Urology, 1998, 160, 1070-1074.	0.4	5
60	Mechanisms and significance of proteinuria. Nephrology, 1995, 1, 95-103.	1.6	4
61	Renal histopathology in US African-Americans with presumed hypertensive nephrosclerosis. Nephrology, 1998, 4, S54-S58.	1.6	3
62	Focal segmental glomerulosclerosis. Pediatric Nephrology, 1996, 10, 374-391.	1.7	3
63	A 51-year-old woman with nephrotic syndrome, hematuria, and renal insufficiency. American Journal of Kidney Diseases, 1997, 29, 806-810.	1.9	2
64	A 19-year-old man with hypertension, proteinuria, and renal insufficiency. American Journal of Kidney Diseases, 1999, 34, 768-774.	1.9	2
65	Persistent Disease Activity in Patients With Long-Standing Glomerular Disease. Kidney International Reports, 2020, 5, 860-871.	0.8	2
66	Mechanisms and Implications of Heterogeneity of Human Glomerulosclerosis1. Contributions To Nephrology, 1996, 118, 6-11.	1.1	1
67	Role of Glomerular Growth Promoters in Progression of Renal Disease.. , 1990, , 21-45.		1
68	Angiotensin II modulates expression of glomerular PDGF. Japanese Journal of Pediatric Nephrology, 1994, 7, 147-149.	0.0	0